Structure and activity relationships of novel uracil derivatives as topical anti-inflammatory agents
摘要:
In order to create novel, topical anti-inflammatory compounds exhibiting more potent activities than lead compound CX-659S (1), we designed and synthesized various derivatives of 1 focusing on the uracil N(l)- and N(3)-substituents, and evaluated their anti-inflammatory activities via inhibition of the picryl chloride-induced contact hypersensitivity reaction (CHR) in mice. In the course of our structure and activity relationship study, we found that compounds 6k, 6q, and 6r inhibited by approximately 50% the CHR, at 0.1 mg/ear. These activities were essentially equipotent with that of Tacrolimus, a strong immunosuppressant. (C) 2003 Elsevier Ltd. All rights reserved.
Novel urea derivatives of the formula ##STR1## wherein R and R.sub.1 are individually selected from the group consisting of hydrogen, chlorine, bromine, nitro, trifluoromethyl, lower alkyl of 1 to 6 carbon atoms and lower alkoxy of 1 to 6 carbon atoms, n is 0 or 1, X is selected from the group consisting of lower alkyl of 1 to 6 carbon atoms optionally substituted with halogen and a nitrogen heterocyclic optionally containing 1 or more other heteroatoms, Y is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and S--Z wherein Z is a nitrogen heterocyclic optionally containing 1 or more other heteroatoms and the dotted lines indicate that the compound of formula I may contain no oxygen bound to the sulfur atom or may be in sulfoxide or sulfonyl form which are useful as herbicides and thereon preparation.
In order to create novel, topical anti-inflammatory compounds exhibiting more potent activities than lead compound CX-659S (1), we designed and synthesized various derivatives of 1 focusing on the uracil N(l)- and N(3)-substituents, and evaluated their anti-inflammatory activities via inhibition of the picryl chloride-induced contact hypersensitivity reaction (CHR) in mice. In the course of our structure and activity relationship study, we found that compounds 6k, 6q, and 6r inhibited by approximately 50% the CHR, at 0.1 mg/ear. These activities were essentially equipotent with that of Tacrolimus, a strong immunosuppressant. (C) 2003 Elsevier Ltd. All rights reserved.